Pulsesight Therapeutics launches to develop non-viral gene therapies for retinal diseases

Feb. 28, 2024

Pulsesight Therapeutics SAS has launched with seed financing, with the aim of developing disruptive non-viral gene therapies with minimally invasive delivery technology.

BioWorld Science Financings Gene therapy Ocular Seed

Today's news in brief

BioWorld

BioWorld briefs for Nov. 13, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 13, 2024.

Gray and green glass dollar symbols with arrow pointing up

Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly

BioWorld

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....

Regulatory actions for Oct. 31, 2024

BioWorld

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...

Australia reimburses Vazkepa a decade after US approval

BioWorld

For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...